Rare paediatric disease voucher programme makes long-awaited US return
After a lengthy period in regulatory limbo, the US Food and Drug Administration’s (FDA) rare paediatric disease priority review voucher (PRV) programme has returned to the pharma landscape, marking a win for biopharma companies developing therapies for …